Scientific conclusions and grounds for the variation to the 
terms of the marketing authorisation(s) 
Active substance(s): efavirenz 
Procedure No. EMEA/H/C/PSUSA/00001200/201804 
Period covered by the PSUR: 17 April 2017 to 16 April 2018 
20 February 2019 
EMA/132484/2019  
Committee for Medicinal Products for Human Use (CHMP) 
Medicinal product no longer authorised
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union  
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
Scientific conclusions  
the CHMP are as follows:  
Taking into account the PRAC Assessment Report on the PSURs for efavirenz, the scientific conclusions of 
the product information. 
efavirenz-containing products.  
authorisations are varied as relevant. 
The CHMP agrees with the scientific conclusions made by the PRAC. 
Grounds for the variation to the terms of the marketing authorisations  
In view of the data presented in the reviewed PSURs, the overall risk-benefit balance of efavirenz is 
therefore considered unchanged in the approved indications provided that the terms of the marketing 
On the basis of the scientific conclusions for efavirenz, the CHMP is of the opinion that the benefit-risk 
balance of the medicinal products containing efavirenz is unchanged subject to the proposed changes to 
For the drug-drug interaction with etonogestrel implant, the PRAC noted the available data from 16 case 
reports and the published literature articles by Vieira et al., 2014 and Chappel et al., 2017. Based on this 
new data, the PRAC considers that the statement that the interaction between etonogestrel and efavirenz 
has not been studied is no longer valid and that this statement should be removed from the SmPC of all 
Medicinal product no longer authorised
The CHMP recommends that the terms of the marketing authorisations should be varied. 
Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)  
EMA/132484/2019 
Page 2/2 
  
  
 
 
 
